Monte Rosa Therapeutics, Inc. (GLUE) intrinsic value & 10-year financials
Monte Rosa Therapeutics, Inc. (GLUE) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 63.5% a year to $123.7M, with an average return on invested capital of -924.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.74
- Market cap
- $809.1M
- Revenue (FY2025)
- $123.7M
- Revenue growth (7-yr CAGR)
- 63.5%
- ROIC (10-yr avg)
- -924.2%
- Free cash flow (FY2025)
- -$27.5M
GLUE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $123.7M | -$38.6M | — | -$27.5M | -43.8% | -60.0% |
| FY2024 | $75.6M | -$72.7M | — | $38.0M | -107.3% | -123.2% |
| FY2023 | $0 | -$135.4M | — | -$62.8M | — | -80.9% |
| FY2022 | — | -$108.5M | — | -$105.4M | — | -85.8% |
| FY2021 | — | -$74.0M | — | -$69.1M | — | -5121.7% |
| FY2020 | — | -$35.9M | — | -$26.4M | — | -73.6% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Monte Rosa Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Monte Rosa Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -79.1% ROIC.
Monte Rosa Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Monte Rosa Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-15.44 per share.